Diabetes 53:185-194, 2004 © 2004 by the American Diabetes Association, Inc. Elevated Mitochondrial Cytochrome P450 2E1 and Glutathione S-Transferase A4-4 in Streptozotocin-Induced Diabetic RatsTissue-Specific Variations and Roles in Oxidative StressDepartment of Animal Biology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
Oxidative stress is an important factor in the etiology and pathogenesis of diabetes. We investigated changes in mitochondrial production of reactive oxygen species (ROS) and mitochondrial antioxidant defense systems in different tissues of streptozotocin (STZ)-induced diabetic rats. Our results show that increased ROS production and oxidative stress differentially affect mitochondrial and cytosolic glutathione (GSH) metabolism. Of the four tissues investigated, the pancreas, kidney, and brain appear to be affected more severely than the liver. We show a five- to eightfold increase of cytochrome P450 2E1 (CYP2E1) and glutathione S-transferase (GST) A4-4 levels in mitochondria from STZ-treated rat tissues compared with those in nondiabetic rat tissues, suggesting possible roles in the disease process. Transient transfection of COS cells with CYP2E1 cDNA caused a similar accumulation of CYP2E1 and GST A4-4 in mitochondria and increased production of mitochondrial ROS. Our results also show an increase in steady-state levels of Hsp70 in the mitochondrial and cytosolic fractions of different tissues of diabetic rats. These results indicate, for the first time, a marked increase in mitochondrial oxidative stress in target tissues of STZ-treated rats and implicate a direct role for mitochondrial CYP2E1 in the generation of intramitochondrial ROS.
Increased cellular oxidative stress and altered antioxidant pool have been implicated in both clinical and experimental type 1 diabetes (1,2). Hyperglycemia, auto-oxidation of glycated proteins, increased production of reactive oxygen species (ROS), decreased antioxidant defense, increased lipid peroxidation, and associated membrane degeneration are implicated as main causes of cellular apoptosis or necrosis, which are common in diabetes (35). Mitochondrial dysfunction, apoptosis, and reduced ATP biosynthesis have all been implicated in type 1 diabetes (6,7). Accumulation of lipid peroxides, 4-hydroxynonenal (HNE), and malonedialdehyde (MDA) in mitochondria has also been reported in diabetic patients, possibly causing further damage to mitochondrial genetic and metabolic systems (8,9). Streptozotocin (STZ), an anolog of N-acetylglucosamine, has been used to generate animal models of type 1 diabetes. Release of nitric oxide, increased glycation of pancreatic proteins, and an increased production of ROS have been proposed as possible causes of STZ-induced pancreatic ß-cell damage (1012). Additionally, STZ has been shown to deplete the antioxidant pool of target cells, thereby making them more susceptible to oxidative damage (13). In STZ-induced diabetic rats, hyperglycemia has been shown to induce typical apoptotic changes in the pancreas and other target tissues (14). Elevated oxidative stress and ROS production in diabetes often parallels an increased expression of cytochrome P450 2E1 (CYP2E1) (14). CYP2E1 is known to metabolize endogenous compounds such as fatty acids, lipid hydroperoxides, and ketone bodies into aldehyde and many xenobiotics and carcinogens into nucleophilic reactive species (14,15). In vitro-reconstituted CYP2E1 and that expressed in intact cells by transient transfection has been shown to produce superoxide (O2·-) and H2O2 (14,15). Several studies have shown increased expression of CYP2E1 in STZ-induced experimental diabetes, human diabetic subjects, obese individuals, and alcohol abusers (1622). The precise intracellular site(s) of CYP2E1 accumulation and ROS production under these pathological conditions, however, remain unclear. The aim of this study was to examine the extent of ROS production, steady-state levels of CYP2E1, and alterations in the antioxidant defense system in the mitochondrial compartment of STZ-induced diabetic rat tissues. Mitochondria are an important source of ROS production and the primary targets of ROS-induced toxicity and apoptosis. Our results show a marked increase in mitochondrial CYP2E1 and glutathione S-transferase (GST) A4-4 and lowered mitochondrial GSH pool in different tissues of STZ-induced diabetic rats. Additionally, transient transfection studies show that mitochondrial CYP2E1 plays a direct role in ROS production. Our results suggest that altered mitochondrial biosynthetic and metabolic activities may be contributing factors in type 1 diabetes.
Most of the biochemicals, enzymes, substrates, and antibodies were purchased from Sigma Chemical (St. Louis, MO). 4-HNE was purchased from Oxis Research (Portland, OR). Polyclonal antibody against CYP2E1 was obtained from Amersham (Piscataway, NJ). Antibody for cytosolic GST A4-4 was a generous gift from Prof. Bengt Mannervik (Upsalla University, Upsalla, Sweden). Antibody against mitochondrial innermembrane translocator protein 44 (TIM44) was a gift from Dr. D. Pain (University of Medicine and Dentistry of New Jersey, Newark, NJ). Cell culture reagents were purchased from Invitrogen (Grand Island, NY). Reagents for electrophoresis and Western blotting and other chemicals were purchased from Bio-Rad (Richmond, CA).
Animals and induction of diabetes.
Isolation of tissues and subcellular fractionations.
Enzyme assay and measurement of oxidative stress.
Transfection of COS cells with CYP2E1 cDNA.
Western blot analysis.
Mitochondrial oxidative stress in STZ-induced diabetes. Blood glucose levels were measured using a glucose oxidase kit from Sigma Chemical. Throughout this study, control rats with a blood glucose level of 85105 mg/dl and diabetic rats (STZ treated) with a level of 300430 mg/dl were used. Figure 1 shows the extent of ROS production and lipid peroxidation in isolated mitochondrial and microsomal membrane fractions from the pancreas, liver, kidney, and brain of control and diabetic rats. Figure 1A (left panel) shows that ROS production in the isolated mitochondrial fractions from different tissues of control rats (180600 light units · min-1 · mg protein-1) was generally higher than with the corresponding microsomal fractions (right panel, 50160 light units · min-1 · mg protein-1). Furthermore, a dramatic 8- to 10-fold increase in ROS production was observed in mitochondria from the pancreas and brain of diabetic rats. A modest but significant increase (P < 0.05) of ROS production (2530%) was observed in mitochondria from the kidney and liver of diabetic rats. With the microsomal fractions of diabetic rats, however, a twofold increase was observed in the pancreas and a 25% increase in the kidney. There was a significant increase in the brain, whereas there was a significant decrease in the liver (Fig. 1A, right panel). Figure 1B shows that total LPO (TBARS) was significantly higher in the mitochondrial fractions of pancreas and liver (68 nmol/mg protein) of control rats than in the microsomal fractions of these tissues (5 nmol/mg protein). The microsomal fractions of kidney and brain, however, showed a two- to threefold higher LPO (1020 nmol/mg protein) than the corresponding mitochondrial fractions (46 nmol/mg protein). Mitochondria from the pancreas, kidney, and brain of diabetic rats showed a 2030% increase in lipid peroxidation, while mitochondria from liver showed 20% reduced activity. The microsomal fractions of the pancreas, kidney, and liver from diabetic rats showed a 1020% increase in TBARS, while microsomes from brain showed a 20% decrease. The reasons for the decreased ROS production in the liver microsome (Fig. 1A, right panel) and decreased TBARS production in liver mitochondria and brain microsomes of diabetic rats, or the physiological significance of these variations, currently remain unclear. These results, however, show that mitochondria from different tissues are important and preferential targets of STZ-induced diabetes.
Mitochondrial and microsomal CYP2E1 levels in STZ-treated rat tissues. A number of studies suggest a possible role for CYP2E1 in ROS production and oxygen-mediated tissue injury (14). We therefore investigated the levels of CYP2E1 in the mitochondrial and microsomal compartments of tissues from diabetic rats. The immunoblot in Fig. 2A (top panel) shows that the steady-state level of the microsomal CYP2E1 in the diabetic pancreas, kidney, and liver was increased by about two to threefold, although the basal activities varied markedly between different tissues. There was no significant increase in the brain microsomes. The levels of CYP2E1 in the mitochondrial fractions of pancreas, kidney, liver, and brain were induced five- to sixfold in diabetic animals. In fact, the steady-state levels of CYP2E1, based on mitochondrial fractions per milligram protein, were higher than in the corresponding microsomal fractions. The levels of calreticulin (Fig. 2, top panel) and TIM44 (bottom panel), used as loading controls, did not vary significantly under the experimental conditions. Furthermore, the microsomal fraction contained very low levels of TIM44, and the mitochondrial fractions contained very low levels of calreticulin, indicating the purity of the respective membrane preparations.
Figure 2B shows the DMNA N-demethylase activity, a marker for CYP2E1 activity, in the mitochondrial (left panel) and microsomal (right panel) fractions of tissues from control and diabetic rats. It is seen that the DMNA activity is increased significantly (2580%) in mitochondria from pancreas, kidney, and liver of diabetic rats. The brain mitochondria from diabetic rats showed only a marginal increase of 10%. The microsomal fractions of pancreas, kidney, and liver also showed a 2550% increase, whereas the brain microsomes showed no increase. Despite a general trend of increased activity, the DMNA activity profile did not directly reflect the CYP2E1 protein level (Fig. 2A), which may indicate altered catalytic activity of the enzyme in diabetic tissues due to either posttranslational modification or other unknown factors. The latter is known to affect the interaction of CYP2E1 with the mitochondrial-specific electron transfer protein, adrenodoxin (Adx) (36).
Mitochondrial and cytosolic GST A4-4 levels in STZ-treated rat tissues.
4-HNE is a preferred substrate for GST A4-4, and CDNB is a general substrate for many different isoforms of GST (28,29). Total GST activity measured with CDNB as the substrate was increased twofold (P 0.05) in the brain mitochondria, while there was a 1015% increase (P > 0.05) in the liver and kidney mitochondria of diabetic rats. There was a reduction in the mitochondrial GST activity in the pancreas (Fig. 4A). CDNB metabolic activity in the cytosol of all tissues, with the exception of the liver, was marginally decreased. Using 4-HNE as a specific substrate for GST A4-4, however, there was a 2050% increase of activity in both the mitochondrial and cytosolic fractions of all four tissues (Fig. 4B). The overall level of 4-HNE metabolism was about two- to threefold higher in the cytosolic than in the mitochondrial fraction. Consistent with the increase of GST A4-4 protein levels, these results show that the mitochondrial 4-HNE metabolism was increased in all four tissues of the diabetic rats studied.
Figure 5A shows that the mitochondrial GSH level in the pancreas, kidney, and liver was moderately increased (2035%) in STZ-induced diabetic animals, whereas brain mitochondria showed an 18% decrease. GSH in the cytosolic fractions was increased only in the liver ( 10%), reduced by 20% in the kidney, and did not vary in the pancreas and brain (Fig. 5A, right panel). These results suggest that either the mitochondrial GSH biosynthesis in the four tissues increases or the cytosolic GSH is transported to mitochondria during STZ-induced diabetes. A similar stress-induced shift in the intracellular GSH pools was shown in a recent study (24).
Figure 5B shows that mitochondrial respiratory chain activity was also affected in STZ-induced diabetes. We observed a 1020% decrease of COX activity in all tissues after STZ administration, and the NADH dehydrogenase activity was increased by 1020%. In all cases, the changes were statistically significant (P 0.05).
Oxidative stress in COS cells transfected with CYP2E1 cDNA.
Increased oxidative stress in COS cells transfected with CYP2E1 was also ascertained by measuring ROS production and LPO and GSH pools in the mitochondrial and microsomal fractions of transfected cells. As shown in Table 1, the mitochondrial ROS in transfected cells was increased by 45%, LPO by 30%, and CYP2E1 activity, as measured by DMNA N-demethylation, increased by 133% compared with mock-transfected cells. The mitochondrial GST activity with CDNB substrate was increased by 44%, whereas that with 4-HNE was increased by 82%. The mitochondrial GSH concentration, however, was not significantly affected by overexpression of CYP2E1. COX activity in the mitochondrial fraction was decreased by 30% in cells transfected with CYP2E1 cDNA. In the microsomal fraction, however, despite a fourfold increase in CYP2E1, the ROS production and LPO level was only marginally (P > 0.05) altered (Table 1). An increase in cytosolic GST activity (5560%) was also observed after CYP2E1 transfection. On the other hand, cytosolic GSH level was not altered significantly (P > 0.05)
We sought direct evidence for the contribution of mitochondrial CYP2E1 in the production of ROS using COS cells transfected with CYP2E1 cDNA. We reasoned that in this system, prevention of flow of electrons from Adx to CYP2E1 should also reduce ROS production. Previous studies from our laboratory (36,37) showed that a peptide corresponding to sequence 265279 of CYP1A1 (36,37), a portion of the helical region that is involved in binding to Adx, can effectively abrogate enzyme activity of both P450MT2 (mitochondrial counterpart of CYP1A1) and P450MT5 (mitochondrial counterpart of CYP2E1). Mitochondria from transfected cells were incubated with wild-type or mutant peptides for 10 min at room temperature and used for assaying ROS production. Table 2 shows that increasing concentrations of wild-type MT2 peptide yielded increasing inhibition (3460%) of ROS production. Mutated MT2 peptide, carrying substitutions at the Adx binding sites, on the other hand, did not inhibit mitochondrial ROS production. Since the MT2 peptide specifically interferes with the interaction of Adx with mitochondrial CYPs, these results conclusively show the role of CYP2E1 in mitochondrial ROS production.
Mitochondria are susceptible to the damaging effects of ROS leading to both accidental cell death (necrosis) and programmed cell death (apoptosis) (38) that are invariably associated with many degenerative disorders (39). In STZ-treated diabetic rats, hyperglycemia induces apoptotic changes and associated oxidative stress (40). Increased oxidative stress and changes in antioxidant pools have been observed in both clinical and experimental diabetes. Mitochondrial ROS generation is thought to be a continuous and normal physiological process, and consequently these organelles contain efficient antioxidant enzyme systems, superoxide dismutase, glutathione peroxidase, glutathione reductase, glutathione transferase, GSH, NADPH, and, finally, the mitochondrial respiration itself (41,42). Various groups, including ours, have reported alterations in the GSH pool and GSH-metabolizing enzymes in addition to increased CYP2E1 expression in STZ-induced diabetic rat tissues (1922). However, most of the studies thus far have focused on the cytosolic and microsomal compartments of target tissues or cells. The present study demonstrates that mitochondria from pancreas, liver, and kidney of STZ-induced diabetic rats exhibit high oxidative stress, induced accumulation of CYP2E1 and GST A4-4, and altered GSH metabolism. Our results also suggest that the mitochondrial CYP2E1 may have a direct role in increased ROS production, while increased GST A4-4 pool may play a protective role. About 12% of oxygen utilized by mitochondria is converted to ROS at intermediate steps of respiratory chain (43). We show here that mitochondrial respiration-linked and NAD(P)H-dependent ROS production is significantly increased in STZ-treated rats. It is likely that increased oxidative stress in the pancreas, the main target in STZ-induced toxicity in type 1 diabetes, may be related to increased tissue degeneration. Indeed, reduced mitochondrial FADH2-driven ATP production and its sequential effects on ATP-dependent K+ channel and voltage-gated Ca2+ channel activities have been implicated as possible causes of reduced insulin secretion in type 1 diabetes (44,45). Consistent with increased mitochondrial ROS production in STZ-induced rat tissues, we also observed increased mitochondrial LPO in the pancreas, kidney, and brain. A reduced mitochondrial ROS in the liver possibly indicates the activation of antioxidant defense systems, leading to rapid detoxification in this tissue. Increased accumulation of 4-HNE, a product of membrane LPO, has also been shown to be involved in tissue degeneration during diabetes (9,46). GST A4-4, the isoenzyme that metabolizes 4-HNE, was found to be induced in both mitochondria and cytosol of different tissues of diabetic animals. Induction of GST A4-4 in these tissues is probably related to accumulation of 4-HNE, which is known to accumulate in tissues of diabetic patients and STZ-treated rats. Accordingly, the mitochondrial activity for 4-HNE metabolism was also increased. Additionally, the GSH pools in the cytosol and in mitochondria also appear to be differentially affected in different tissues. While the mitochondrial GSH pool in the pancreas, kidney, and liver was slightly increased, the cytosolic GSH pool in the kidney was significantly reduced, suggesting a difference in activation of antioxidant pathways in different tissues. A number of studies suggest that CYP2E1 contributes to ROS production during NADPH-dependent metabolism of substrates (47). A majority of studies, however, are based on in vitro reconstitution with purified enzymes and electron transfer proteins or reconstituted microsomal membrane fragments. These observations, coupled to results showing increased steady-state levels of microsomal CYP2E1 in diabetes, have prompted the possibility that this heme protein may contribute to oxidative stress and disease complications in diabetes. An increased production of ketone bodies and lipolysis during diabetes is the other factor influencing the expression of CYP2E1 in tissues. We have observed a marked induction of CYP2E1 protein and an increase in CYP2E1-dependent DMNA metabolism in subcellular compartments of different tissues of STZ-treated diabetic rats. The brain, which becomes the main user of ketone bodies in diabetes, shows a minimal level of CYP2E1 induction. Mitochondrial respiratory chain is the main site of ROS production, especially at the level of NADH dehydrogenase and COX complexes (48). In our study, we found a moderate increase in NADH dehydrogenase activity in tissues of STZ-treated rats. A decrease in the terminal COX activity was also seen in diabetic rats. An increase in NADH dehydrogenase and a decrease in COX activities may promote leakage of electrons from the mitochondrial inner membrane-associated electron transport complexes contributing to the increased mitochondrial ROS production in tissues from STZ-treated rats. Previous studies from our laboratory showed that mitochondrial-targeted, hyperphosphorylated CYP2E1 exhibits a preference for the mitochondrial electron transfer proteins, Adx and Adx reductase (Adr), for activity. We also showed that a peptide designated as MT2 peptide (36), corresponding to the Adx-interacting domain of CYPMT2 (truncated CYP1A1), effectively inhibited mitochondrial CYP2E1-dependent DMNA activity. In the present study, we investigated the role of mitochondrial CYP2E1 in ROS production by transient transfection of CYP2E1 cDNA in COS cells. Our results showed that an increased mitochondrial accumulation of CYP2E1 was accompanied by an increase in mitochondrial ROS production, increased LPO, and alterations in subcellular GSH metabolism. A preferential accumulation of CYP2E1 in mitochondria was also accompanied by a lower COX activity and increased 4-HNE metabolism indicated by increased GST A4-4 level. An important observation of this study relates to the vastly reduced level of ROS production in mitochondrial isolates from CYP2E1 transfected cells by incubation with wild-type MT2 peptide, which selectively interferes with CYP interaction with Adx. These results suggest that disruption of electron flow from Adx to CYP2E1 causes a vastly reduced ROS production. Our results therefore provide a direct role for mitochondrial CYP2E1 in ROS production. Since increased mitochondrial accumulation of CYP2E1 in transfected cells also caused a steady and continuous inhibition of COX activity, we hypothesize that mitochondrial CYP2E1 is probably the important initial contributor of mitochondrially generated ROS that subsequently causes altered electron transfer chain activity. In summary, we provide evidence for increased mitochondrial oxidative stress in STZ-treated diabetic rat tissues. The extent of increase in stress, steady-state levels of CYP2E1, and activation of GSH-dependent oxidant metabolism are differentially affected in different tissues. These results provide insight for controlling or preventing oxidative injury in different target tissues during diabetes.
This work was supported by National Institute of Health Grant GM-34883-18 (to N.G.A.). Support from the research committee (Faculty of Medicine and Health Sciences, United Arab Emirates University; to H.R.) is also acknowledged. We thank members of the Avadhani lab for valuable suggestions and criticisms.
H.R. is on leave from the Department of Biochemistry, Faculty of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates. M.-A.R. is currently located at INSERM U481, Faculté de Médecine Xavier Bichat, Paris, France. Address correspondence and reprint requests to Narayan G. Avadhani, Department of Animal Biology, School of Veterinary Medicine, University of Pennsylvania, 3800 Spruce St., Philadelphia, PA 19104. E-mail: narayan{at}vet.upenn.edu Received for publication July 16, 2003 and accepted in revised form October 6, 2003
Abbreviations: Adx, adrenodoxin; CDNB, 1 chloro-2,4-dinitrobenzene; COX, cytochrome c oxidase; CYP2E1, cytochrome P450 2E1; DMNA, dimethylnitrosamine; GST, glutathione S-transferase; HNE, 4-hydroxynonenal; LPO, lipid peroxidation; MDA, malonedialdehyde; ROS, reactive oxygen species; STZ, streptozotocin; TBARS, thiobarbituric acid-reactive substances; TIM44, mitochondrial innermembrane translocator protein 44
This article has been cited by other articles:
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||